Company intelligence / Profile preview

Morningside Group

Newton Centre, Massachusetts, United States

Ownership: Private
Employees: ~57
Development stage: Other

Overview

Morningside Group is a long-established venture capital and private equity investor focused on life sciences, healthcare, biotech, digital health, and technology. Its portfolio includes oncolytic viral therapy, mitochondrial medicine, diagnostics (e.g., Geneoscopy, Cyted, Alamar Biosciences), as well as investments in companies targeting tuberculosis, hepatitis B, asthma, autism, dementia, and more.

Therapeutic areas: Other
Modalities: Not applicable (investor, not developer)
Industry: Investors

Partnerships

Portfolio investments in biotech companies (e.g., Apellis, Rona Therapeutics, CellCentric)

Beyond the preview

Go deeper on Morningside Group.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Morningside Group.

Explore the full profile